Litcius/Paper detail

Cytokine and Chemokine Retention Profile in COVID-19 Patients with Chronic Kidney Disease

Paola Ciceri, Valeria Bono, Lorenza Magagnoli, Matteo Sala, Antonella d’Arminio Monforte, Andrea Galassi, Alessandra Barassi, Giulia Marchetti, Mario Cozzolino

2022Toxins14 citationsDOIOpen Access PDF

Abstract

Chronic kidney disease (CKD) patients are more susceptible to infections compared to the general population. SARS-CoV-2 virus pathology is characterized by a cytokine storm responsible for the systemic inflammation typical of the COVID-19 disease. Since CKD patients have a reduced renal clearance, we decided to investigate whether they accumulate harmful mediators during the COVID-19 disease. We conducted a retrospective study on 77 COVID-19 hospitalized subjects in the acute phase of the illness. Thirteen different cytokines were assessed in plasma collected upon hospitalization. The patients were divided into three groups according to their estimated glomerular filtration rate, eGFR < 30 (n = 23), 30 < eGFR < 60 (n = 33), eGFR > 60 mL/min (n = 21). We found that Tumor Necrosis Factor α and its receptors I and II, Interleukin-7, Leukemia Inhibitory Factor, FAS receptor, Chitinase 3-like I, and the Vascular Endothelial Growth Factor showed an increased accumulation that negatively correlate with eGFR. Moreover, non-survivor patients with an impaired kidney function have significantly more elevated levels of the same mediators. In conclusion, there is a tendency in COVID-19 ESRD patients to accumulate harmful cytokines. The accumulation seems to associate with mortality outcomes and may be due to reduced clearance but also to increased biosynthesis in most severe cases.

Topics & Concepts

MedicineRenal functionKidney diseaseCytokineInternal medicinePopulationImmunologyKidneyProinflammatory cytokineChemokineGastroenterologyInflammationEnvironmental healthCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19COVID-19 and healthcare impacts